MHRA Chief Underlines Support For UK Innovation In Any Brexit Scenario
MHRA chief executive emphasizes at a conference in Mumbai the agency's continued commitment to supporting innovation in the UK, regardless of the outcome of Brexit.
You may also be interested in...
The reduction in the European Medicines Agency’s activities since the UK voted to leave the EU nearly three years has impaired the regulator's ability to keep up with scientific and regulatory developments, and it is facing more staff losses as a result of its relocation to the Netherlands. However, the agency says it has managed to safeguard its core activities relating to the evaluation and supervision of medicines, and that the EU regulatory network should be able to adapt to Brexit-related changes without jeopardizing the quality of its work.
A new leader is needed for MHRA as UK agency CEO Ian Hudson announces he'll leave next September. Someone else will have to reshape and guide the agency after Brexit.
Astellas’s senior director, head of enterprise insights and digital solutions, digital, analytics and technology tells Scrip how data analytics and deductive hypothesis-oriented simulation are driving improved strategic decision-making across the organization. He also outlined some early generative AI use cases and the promise of digital twins in medicine.